Letters to the Editor: The National Institutes of Health Grants Peer Review Study Team

1976 ◽  
Vol 04 (02) ◽  
pp. 201-205

Please refer to fulltext.

2008 ◽  
Vol 64 (5) ◽  
pp. A15-A17 ◽  
Author(s):  
S. Claiborne Johnston ◽  
Stephen L. Hauser

2006 ◽  
Vol 54 (1) ◽  
pp. 13-19 ◽  
Author(s):  
Theodore A. Kotchen ◽  
Teresa Lindquist ◽  
Anita Miller Sostek ◽  
Raymond Hoffmann ◽  
Karl Malik ◽  
...  

1992 ◽  
Vol 6 (7) ◽  
pp. 2384-2385
Author(s):  
Mushtaq A. Khan ◽  
Johnny W. Wortham ◽  
Nathan Watzman ◽  
Jerome G. Green

2020 ◽  
Vol 6 (23) ◽  
pp. eaaz4868 ◽  
Author(s):  
Elena A. Erosheva ◽  
Sheridan Grant ◽  
Mei-Ching Chen ◽  
Mark D. Lindner ◽  
Richard K. Nakamura ◽  
...  

Previous research has found that funding disparities are driven by applications’ final impact scores and that only a portion of the black/white funding gap can be explained by bibliometrics and topic choice. Using National Institutes of Health R01 applications for council years 2014–2016, we examine assigned reviewers’ preliminary overall impact and criterion scores to evaluate whether racial disparities in impact scores can be explained by application and applicant characteristics. We hypothesize that differences in commensuration—the process of combining criterion scores into overall impact scores—disadvantage black applicants. Using multilevel models and matching on key variables including career stage, gender, and area of science, we find little evidence for racial disparities emerging in the process of combining preliminary criterion scores into preliminary overall impact scores. Instead, preliminary criterion scores fully account for racial disparities—yet do not explain all of the variability—in preliminary overall impact scores.


2021 ◽  
Vol 4 (1) ◽  
Author(s):  
John L. Reed ◽  
Thomas E. Gutwein

Study hypothesis  The costs of anti-epileptic medication (AED) and poor care coordination result in increased Emergency Department (ED) visits for seizure events and produce both direct and indirect economic burdens on patients with frequent seizures.    Methods  A retrospective chart review study of ED visits with chief concern of seizure from two hospitals over a two-year period was performed; resulting in 152 visits recorded in this study.  Data collected included demographic information, relevant seizure or past medical history (PMH), diagnostics performed in the ED, and the admission status of the patient along with the total charges per encounter.  Data was analyzed descriptively and with logistic regression analysis.    Results  The results yielded by this study were generally in-line with the results of similar studies, indicating a higher relative rate of ED seizure visits for males, people of Black race, and infant and toddler populations. A high proportion of Medicaid/Medicare coverage and indiscernible employment status for most patients were also noted.  Observed differences in average cost among patients with and without epilepsy and male versus female patients were not shown to be statistically significant.  However, the increased likelihood of admission with increasing age was shown to be significant with an average age difference between admitted and discharged populations of approximately 10 years (p= 0.003).    Conclusions  The data provided here is not sufficient to examine the complex relationship between seizures, epilepsy, and costs among various other patient factors.  Further study is necessary to minimize direct and indirect costs of seizures.    Acknowledgments  This project was funded, in part, with support from the Indiana Clinical and Translational Sciences Institute funded, in part by UL1TR002529 from the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. 


2017 ◽  
Author(s):  
Samet Keserci ◽  
Eric B. Livingston ◽  
Lingtian Wan ◽  
Alexander R. Pico ◽  
George Chacko

AbstractDrug discovery and subsequent availability of a new breakthrough therapeutic or ‘cure’ is a compelling example of societal benefit from research advances. These advances are invariably collaborative, involving the contributions of many scientists to a discovery network in which theory and experiment are built upon. To understand such scientific advances, data mining of public and commercial data sources coupled with network analysis can be used as a digital methodology to assemble and analyze component events in the history of a therapeutic. This methodology is extensible beyond the history of therapeutics and its use more generally supports (i) efficiency in exploring the scientific history of a research advance (ii) documenting and understanding collaboration (iii) portfolio analysis, planning and optimization (iv) communication of the societal value of research. As a proof of principle, we have conducted a case study of five anti-cancer therapeutics. We have linked the work of roughly 237,000 authors in 106,000 scientific publications that capture the research crucial for the development of these five therapeutics. We have enriched the content of networks of these therapeutics by annotating them with information on research awards as well as peer review that preceded these awards. Applying retrospective citation discovery, we have identified a core set of publications cited in the networks of all five therapeutics and additional intersections in combinations of networks as well as awards from the National Institutes of Health that supported this research. Lastly, we have mapped these awards to their cognate peer review panels, identifying another layer of collaborative scientific activity that influenced the research represented in these networks.


Sign in / Sign up

Export Citation Format

Share Document